Organon & Co (OGN) - Financial and Strategic SWOT Analysis Review

Organon & Co (OGN) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Organon & Co (Organon) is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access programs, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It collaborates with pharmaceutical and biopharmaceutical businesses to market its products. Organon is headquartered in Jersey City, New Jersey, the US.

Organon & Co Key Recent Developments

May 02,2024: Organon Reports Results for the First Quarter Ended March 31, 2024
Feb 15,2024: Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb 01,2024: Organon to Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
Nov 02,2023: Organon Reports Results for the Third Quarter Ended September 30, 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Organon & Co - Key Facts
Organon & Co - Key Employees
Organon & Co - Key Employee Biographies
Organon & Co - Major Products and Services
Organon & Co - History
Organon & Co - Company Statement
Organon & Co - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Organon & Co - Business Description
Product Category: Biosimilars
Overview
Performance
Product Category: Established Brands
Overview
Performance
Product Category: Other
Overview
Performance
Product Category: Women’s Health
Overview
Performance
Geographical Segment: Asia Pacific and Japan
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe and Canada
Performance
Geographical Segment: Latin America, Middle East, Russia and Africa
Performance
Geographical Segment: Other
Performance
Geographical Segment: United States
Performance
R&D Overview
Organon & Co - Corporate Strategy
Organon & Co - SWOT Analysis
SWOT Analysis - Overview
Organon & Co - Strengths
Organon & Co - Weaknesses
Organon & Co - Opportunities
Organon & Co - Threats
Organon & Co - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Organon & Co, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Organon & Co, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Organon & Co, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 02, 2024: Organon Reports Results for the First Quarter Ended March 31, 2024
Feb 15, 2024: Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb 01, 2024: Organon to Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
Nov 02, 2023: Organon Reports Results for the Third Quarter Ended September 30, 2023
Sep 05, 2023: Organon Bolsters Research & Development Expertise with Two Leadership Appointments
Aug 08, 2023: Organon Reports Results for the Second Quarter Ended June 30, 2023
Aug 04, 2023: Senderra Specialty Pharmacy announces that HUMIRA biosimilar products are now available to patients nationwide
Jun 07, 2023: Organon and CAF, Development Bank of Latin America, Launch First-Of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
May 04, 2023: Organon reports results for the first quarter ended March 31, 2023
Mar 07, 2023: Organon launches “Her Plan is Her Power,” a New Global Initiative to reduce unplanned pregnancies where need is great and disparities exist
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Organon & Co, Key Facts
Organon & Co, Key Employees
Organon & Co, Key Employee Biographies
Organon & Co, Major Products and Services
Organon & Co, History
Organon & Co, Subsidiaries
Organon & Co, Key Competitors
Organon & Co, Ratios based on current share price
Organon & Co, Annual Ratios
Organon & Co, Annual Ratios (Cont...1)
Organon & Co, Annual Ratios (Cont...2)
Organon & Co, Interim Ratios
Organon & Co, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Organon & Co, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Organon & Co, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Organon & Co, Performance Chart (2019 - 2023)
Organon & Co, Ratio Charts
Organon & Co, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Organon & Co, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings